Extending their partnership to an eighth company, La Jolla’s Avalon Ventures and UK-based drug giant GSK said Friday they have formed another San Diego biotech startup.
Johns Hopkins University President Ronald J. Daniels was among the speakers Thursday at the fifth annual U.S. News & World Report STEM Solutions National Leadership Conference in Baltimore.
The three-day conference brought together leaders from academia, business, and government to contribute key insights into science, technology, engineering, and mathematics—or STEM—education. The summit focused on solutions and best practices to ensure that the nation’s future workforce has the necessary skills and knowledge to thrive in a global economy.
Roche Venture Fund and 5AM Ventures have led Purigen Biosystems to an $18.2 million Series A round. Purigen will use the money to advance the development and commercialization of a benchtop system for extracting, quantifying and enriching of samples for genomic testing.
TEDCO handed out its annual honors for “Innovation,” “Corporate Excellence” and “Entrepreneurship” on Tuesday. The ICE Awards ceremony at Columbus Center in Inner Harbor marked a move into Baltimore city after last year’s event in Columbia.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
Roche Holding (RHHBY – Analyst Report) announced that the FDA has granted accelerated approval to its cancer immunotherapy drug, Tecentriq (atezolizumab), for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC), who experienced disease progression during or after platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
Decades of research have linked specific personality traits to a longer life expectancy. Some of them — from friendliness to emotional stability — may be written into our genes.
And while one study found that we’re not particularly good at identifying these traits in ourselves, it suggested that our close friends are often spot-on.
What 4000+ corporate directors think about the economy, risk, board strengths and weaknesses, and boardroom diversity
“Boards cannot afford to have directors around the table who aren’t delivering value,” says a new report based on the 2016 Global Board of Directors Survey, released from Professor Boris Groysberg and Yo-Jud Cheng of Harvard Business School, Spencer Stuart, the WomenCorporateDirectors (WCD) Foundation, and researcher Deborah Bell. With greater institutional and activist shareholder activity and stronger concerns about risk and global competitive threats, boards are taking on “a more strategic, dynamic, and responsive role” in their companies, the report states – pushing “issues around board composition and diversity to the fore.”
Kevin Plank encourages University of Maryland graduates to let “passion” fuel their dreams Kevin Plank remembers sitting in his cap and gown at the University of Maryland, College Park commencement ceremony in 1996 as Hillary Clinton spoke to his graduating class. He also remembers that he was fidgeting in his seat and only half-listening.
The National Human Genome Research Institute of the National Institutes of Health (NIH) has awarded the Johns Hopkins Berman Institute of Bioethics a “Center of Excellence” grant to study the ethical, legal and social implications (ELSI) of applying genomics to research on, and the prevention and treatment of, infectious disease. This builds on three years of work of an exploratory Center of Excellence in ELSI Research (CEER) at the Berman Institute, the first such project to focus attention on genomic ELSI issues in the context of infectious disease.